HC Wainwright Reaffirms Buy Rating for Citius Pharmaceuticals (NASDAQ:CTXR)

HC Wainwright reissued their buy rating on shares of Citius Pharmaceuticals (NASDAQ:CTXR) in a report issued on Tuesday morning,Benzinga reports. HC Wainwright currently has a $4.00 price objective on the stock. HC Wainwright also issued estimates for Citius Pharmaceuticals’ Q4 2024 earnings at ($0.08) EPS, FY2024 earnings at ($0.26) EPS, Q1 2025 earnings at ($0.05) EPS, Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.18) EPS and FY2026 earnings at $0.05 EPS.

Separately, EF Hutton Acquisition Co. I raised Citius Pharmaceuticals to a “strong-buy” rating in a research report on Monday, July 15th.

Citius Pharmaceuticals Stock Down 39.1 %

NASDAQ:CTXR opened at $0.20 on Tuesday. The stock has a market capitalization of $36.15 million, a price-to-earnings ratio of -1.34 and a beta of 1.66. Citius Pharmaceuticals has a 52 week low of $0.19 and a 52 week high of $1.07. The firm has a 50 day moving average of $0.44 and a 200 day moving average of $0.60.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets lifted its holdings in shares of Citius Pharmaceuticals by 88.5% during the first quarter. BNP Paribas Financial Markets now owns 69,615 shares of the company’s stock worth $62,000 after purchasing an additional 32,686 shares during the period. Miller Investment Management LP increased its stake in shares of Citius Pharmaceuticals by 99.3% in the third quarter. Miller Investment Management LP now owns 99,640 shares of the company’s stock worth $50,000 after acquiring an additional 49,640 shares during the period. Point72 DIFC Ltd purchased a new position in shares of Citius Pharmaceuticals during the second quarter worth $29,000. Arkadios Wealth Advisors lifted its position in Citius Pharmaceuticals by 33.3% during the third quarter. Arkadios Wealth Advisors now owns 200,000 shares of the company’s stock valued at $100,000 after purchasing an additional 50,000 shares during the period. Finally, Wealth Advisory Solutions LLC boosted its holdings in Citius Pharmaceuticals by 33.1% in the third quarter. Wealth Advisory Solutions LLC now owns 201,000 shares of the company’s stock valued at $101,000 after purchasing an additional 50,000 shares during the last quarter. Hedge funds and other institutional investors own 16.88% of the company’s stock.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.